tradmap

ALGS Aligos Therapeutics, Inc.

$5.30 -1.12%

Healthcare · Biological Products, (No Diagnostic Substances)

Aligos Therapeutics, Inc. (ALGS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $33 million. Shares last traded at $5.30, 61.0% below their 52-week high. Over the past year the stock is down 29.3%. Net profit margin is -1106.7%, below the peer median of 6.3%. Revenue declined 39.5% year over year.

Market Cap
$33M
Shares Out
6.2M
EPS (TTM)
$-1.86
P/E Ratio
P/S Ratio
15.02
P/B Ratio
1.03
Dividend / Share
Dividend Yield
52-Week High
$13.61
52-Week Low
$4.82
Volume
1,095
Avg Vol (3m)
4,205.175

Performance

1W
-0.47%
1M
+1.63%
3M
-26.68%
6M
-52.51%
YTD
-42.09%
1Y
-29.27%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.71
SMA (50)
$6.10
SMA (200)
$8.07
Price vs SMA50
-12.98%
Price vs SMA200
-34.27%
ATR (14)
$0.37

Financials

Revenue
$2M
Net Income
$-24M
Gross Margin
Operating Margin
-4024.9%
Net Margin
-1106.7%
Return on Equity
-76.1%
Return on Assets
-37.5%
Current Ratio
2.56
Debt / Equity
1.03
Revenue Growth (YoY)
-39.5%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-2.21 2026-05-07
FY 2025 $-2.45 2026-03-05
Q3 2025 $-0.44 2025-11-06
Q2 2025 $2.90 2025-08-06
Q1 2026 $-2.11 2026-05-07
FY 2025 $-20.94 2026-03-05

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ALGS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
15.02 / 5.21 med
+188% premium
Net margin vs peers
-1106.7% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.